NVP-BEZ235
PI 3-K and mTOR inhibitor / A dual PI3K and mTOR kinase inhibitor1. It inhibits VEGF-induced proliferation and angiogenesis2. Reverses lapatinib resistance3. It induces G1 arrest and reduces cyclin D1 expression in melanoma cells with negligible apoptosis4. Inhibits the growth of cancer cells with activating PI3K mutations5. Active in vivo.
Biochemicals & reagents
915019-65-7
1) Maira et al. (2008), Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian targe of rapamycin inhibitor with poten in vivo antitumor activity; Mol. Cancer Ther., 7 1851 2) Schnell et al. (2008), Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin iinhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging; Cancer Res., 68 6598 3) Eichhorn et al. (2008), Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/Phosphatidylinositol 3-kinase inhibitor NVP-BEZ235; Cancer Res., 68 9221 4) Marone et al. (2009), Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors; Mol. Cancer Res., 7 601 5) Serra et al. (2008), NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations; Cancer Res., 68 8022
-20°C
TARGET: Kinase -- PATHWAY: PI3K; Cell cycle; mTOR; Proliferation; Autophagy -- RESEARCH AREA: Angiogenesis; Cell death -- DISEASE AREA: Cancer